InVitria Announces Launch of Recombinant Albumin for Diagnostics
Product News Apr 20, 2009
InVitria’s Recombinant Albumin-DX eliminates safety concerns, stabilizes sensitive biomarkers and enhances diagnostic performance by improving specificity, according to company.
Addressing product safety and consistency issues in the human diagnostics market, InVitria has announced the commercial launch of two protease-free recombinant albumin products.
InVitria’s Recombinant Albumin-DX and Recombinant Albumin-DX (Lipid-Free) perform better in diagnostics applications than both bovine serum albumin (BSA) and plasma-derived human serum albumin (pHSA).
The advantages of Recombinant Albumin-DX include:
Reduce non-specific binding and improve specificity;
• Improved consistency due to recombinant manufacturing;
• Improved stabilization of sensitive proteins and biomarkers; and
• Reduce occupational safety risk and regulatory burden of handling human or animal blood products.
Customer testing has shown that Recombinant Albumin-DX (Lipid-Free) increased biomarker activity to levels twice as high as the current commercial alternative.
In addition, stability over time was significantly improved with Recombinant Albumin-DX (Lipid-Free). Tests have also shown the bioequivalence of the Recombinant Albumin-DX to native human serum albumin (HSA).
“InVitria is committed to developing high performance, regulatory friendly products for the diagnostics market and our Recombinant Albumin-DX and DX Lipid-Free products deliver on this promise,” said the company’s President and CEO Scott Deeter. “Recombinant Album-DX and DX Lipid-Free provide the specificity, stability and consistency that diagnostic customers seek.”